Matthew Volm

671 total citations
17 papers, 492 citations indexed

About

Matthew Volm is a scholar working on Oncology, Pathology and Forensic Medicine and Molecular Biology. According to data from OpenAlex, Matthew Volm has authored 17 papers receiving a total of 492 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 6 papers in Pathology and Forensic Medicine and 5 papers in Molecular Biology. Recurrent topics in Matthew Volm's work include Cancer Treatment and Pharmacology (7 papers), Viral-associated cancers and disorders (4 papers) and Lymphoma Diagnosis and Treatment (4 papers). Matthew Volm is often cited by papers focused on Cancer Treatment and Pharmacology (7 papers), Viral-associated cancers and disorders (4 papers) and Lymphoma Diagnosis and Treatment (4 papers). Matthew Volm collaborates with scholars based in United States and Canada. Matthew Volm's co-authors include Silvia C. Formenti, Franco M. Muggia, Jamie H. Von Roenn, Ruth Oratz, W. Fraser Symmans, Sandra Demaria, Richard L. Shapiro, Herman Yee, Heather McMullen and Paula Klein and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and The Oncologist.

In The Last Decade

Matthew Volm

17 papers receiving 475 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Matthew Volm United States 10 259 140 119 115 78 17 492
D. Hungermann Germany 11 265 1.0× 196 1.4× 173 1.5× 136 1.2× 75 1.0× 23 555
T. Rinda Soong United States 12 124 0.5× 113 0.8× 106 0.9× 69 0.6× 75 1.0× 35 475
D. Paraïso France 14 272 1.1× 55 0.4× 149 1.3× 78 0.7× 96 1.2× 35 689
Carlo Alberto Giorgi Italy 12 280 1.1× 175 1.3× 51 0.4× 58 0.5× 112 1.4× 35 513
Felipe G. Gercovich Argentina 7 218 0.8× 86 0.6× 83 0.7× 107 0.9× 101 1.3× 29 439
TW Mak Canada 9 198 0.8× 56 0.4× 144 1.2× 290 2.5× 47 0.6× 13 671
Betsy O. Spaulding United States 16 312 1.2× 216 1.5× 348 2.9× 84 0.7× 178 2.3× 19 725
Fanqi Bai United States 13 305 1.2× 62 0.4× 290 2.4× 192 1.7× 60 0.8× 24 1.0k
Candida Vitale Italy 16 358 1.4× 44 0.3× 160 1.3× 244 2.1× 46 0.6× 46 832
Steven Piver United States 15 119 0.5× 112 0.8× 145 1.2× 70 0.6× 91 1.2× 25 682

Countries citing papers authored by Matthew Volm

Since Specialization
Citations

This map shows the geographic impact of Matthew Volm's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Matthew Volm with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Matthew Volm more than expected).

Fields of papers citing papers by Matthew Volm

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Matthew Volm. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Matthew Volm. The network helps show where Matthew Volm may publish in the future.

Co-authorship network of co-authors of Matthew Volm

This figure shows the co-authorship network connecting the top 25 collaborators of Matthew Volm. A scholar is included among the top collaborators of Matthew Volm based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Matthew Volm. Matthew Volm is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Singh, Jasmeet, Yelena Novik, Stacey Stein, et al.. (2014). Phase 2 trial of everolimus and carboplatin combination in patients with triple negative metastatic breast cancer. Breast Cancer Research. 16(2). R32–R32. 68 indexed citations
2.
Singh, Jasmeet, Matthew Volm, Julia Smith, et al.. (2013). RAD001-carboplatin combination in triple-negative metastatic breast cancer (TNMBC): A phase II trial.. Journal of Clinical Oncology. 31(15_suppl). 1042–1042. 3 indexed citations
3.
Singh, Jasmeet, Matthew Volm, Julia Smith, et al.. (2012). Phase II trial of RAD001 plus carboplatin in patients with triple-negative metastatic breast cancer.. Journal of Clinical Oncology. 30(15_suppl). e11529–e11529. 4 indexed citations
4.
Singh, Jasmeet, Matthew Volm, Yelena Novik, et al.. (2012). Efficacy of RAD001/carboplatin in triple-negative metastatic breast cancer: A phase II study.. Journal of Clinical Oncology. 30(27_suppl). 108–108. 2 indexed citations
5.
Andreopoulou, Eleni, Eugene S. Kim, Matthew Volm, et al.. (2007). Feasibility and Cardiac Safety of Pegylated Liposomal Doxorubicin plus Trastuzumab in Heavily Pretreated Patients with Recurrent HER2-Overexpressing Metastatic Breast Cancer. Clinical Breast Cancer. 7(9). 690–696. 22 indexed citations
6.
Schwartz, Jonathan D., Max W. Sung, Myron Schwartz, et al.. (2005). Thalidomide in Advanced Hepatocellular Carcinoma with Optional Low-Dose Interferon-α2a upon Progression. The Oncologist. 10(9). 718–727. 24 indexed citations
7.
Volm, Matthew. (2003). Male breast cancer. Current Treatment Options in Oncology. 4(2). 159–164. 26 indexed citations
8.
Haigentz, Missak, Mimi Kim, Joan Sorich, et al.. (2003). Phase I study of amifostine as a cytoprotector of the gemcitabine/cisplatin combination in patients with advanced solid malignancies. Anti-Cancer Drugs. 14(4). 321–326. 4 indexed citations
9.
Formenti, Silvia C., Matthew Volm, Kristin A. Skinner, et al.. (2003). Preoperative Twice-Weekly Paclitaxel With Concurrent Radiation Therapy Followed by Surgery and Postoperative Doxorubicin-Based Chemotherapy in Locally Advanced Breast Cancer: A Phase I/II Trial. Journal of Clinical Oncology. 21(5). 864–870. 93 indexed citations
10.
Holkova, Beata, Kenichi Takeshita, Debbie M. Cheng, et al.. (2001). Effect of Highly Active Antiretroviral Therapy on Survival in Patients With AIDS-Associated Pulmonary Kaposi’s Sarcoma Treated With Chemotherapy. Journal of Clinical Oncology. 19(18). 3848–3851. 60 indexed citations
11.
Symmans, W. Fraser, Matthew Volm, Richard L. Shapiro, et al.. (2000). Paclitaxel-induced apoptosis and mitotic arrest assessed by serial fine-needle aspiration: implications for early prediction of breast cancer response to neoadjuvant treatment.. PubMed. 6(12). 4610–7. 119 indexed citations
12.
Volm, Matthew & Jamie H. Von Roenn. (1999). AIDS-associated lymphoma. Cancer treatment and research. 99. 241–266. 5 indexed citations
13.
Volm, Matthew, Mark S. Talamonti, Maya Thangavelu, & William J. Gradishar. (1997). Pituitary adenoma and bilateral male breast cancer: An unusual association. Journal of Surgical Oncology. 64(1). 74–78. 32 indexed citations
14.
Kramer, Elissa L., Matthew Volm, Bernadine R. Donahue, et al.. (1997). Tc-99m LL-2 fab' monoclonal antibody imaging in acquired immune deficiency syndrome-related lymphoma. Cancer. 80(S12). 2469–2477. 1 indexed citations
15.
Volm, Matthew & Jamie H. Von Roenn. (1996). Non–AIDS-defining malignancies in patients with HIV infection. Current Opinion in Oncology. 8(5). 386–391. 14 indexed citations
16.
Volm, Matthew & Jamie H. Von Roenn. (1995). Treatment strategies for epidemic Kaposiʼs sarcoma. Current Opinion in Oncology. 7(5). 429–436. 11 indexed citations
17.
Volm, Matthew & Martin S. Tallman. (1995). Developments in the treatment of acute leukemia in adults. Current Opinion in Oncology. 7(1). 28–35. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by D. Hungermann Breakdown of academic impact, for papers by T. Rinda Soong Breakdown of academic impact, for papers by D. Paraïso Breakdown of academic impact, for papers by Carlo Alberto Giorgi Breakdown of academic impact, for papers by Felipe G. Gercovich Breakdown of academic impact, for papers by TW Mak Breakdown of academic impact, for papers by Betsy O. Spaulding Breakdown of academic impact, for papers by Fanqi Bai Breakdown of academic impact, for papers by Candida Vitale Breakdown of academic impact, for papers by Steven Piver
Rankless by CCL
2026